Literature DB >> 10520778

Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction.

C M Gibson1, K A Ryan, S A Murphy, R Mesley, S J Marble, R P Giugliano, C P Cannon, E M Antman, E Braunwald.   

Abstract

OBJECTIVES AND
BACKGROUND: While attention has focused on coronary blood flow in the culprit artery in acute myocardia infarction (MI), flow in the nonculprit artery has not been studied widely, in part because it has been assumed to be normal. We hypothesized that slower flow in culprit arteries, larger territories infarcted and hemodynamic perturbations may be associated with slow flow in nonculprit arteries.
METHODS: The number of frames for dye to first reach distal landmarks (corrected TIMI [Thrombolysis in Acute Myocardial Infarction] frame count [CTFC]) were counted in 1,817 nonculprit arteries from the TIMI 4, 10A, 10B and 14 thrombolytic trials.
RESULTS: Nonculprit artery flow was slowed to 30.9 +/- 15.0 frames at 90 min after thrombolytic administration, which is 45% slower than normal flow in the absence of acute MI (21 +/- 3.1, p < 0.0001). Patients with TIMI grade 3 flow in the culprit artery had faster nonculprit artery CTFCs than those patients with TIMI grades 0, 1 or 2 flow (29.1 +/- 13.7, n = 1,050 vs. 33.3 +/- 16.1, n = 752, p < 0.0001). The nonculprit artery CTFC improved between 60 and 90 min (3.3 +/- 17.9 frames, n = 432, p = 0.0001), and improvements were related to improved culprit artery flow (p = 0.0005). Correlates of slower nonculprit artery flow included a pulsatile flow pattern (i.e., systolic flow reversal) in the nonculprit artery (p < 0.0001) and in the culprit artery (p = 0.01), a left anterior descending artery culprit artery location (p < 0.0001), a decreased systolic blood pressure (p = 0.01), a decreased ventriculographic cardiac output (p = 0.02), a decreased double product (p = 0.0002), a greater percent diameter stenosis of the nonculprit artery (p = 0.01) and a greater percent of the culprit artery bed lying distal to the stenosis (p = 0.04). Adjunctive percutaneous transluminal coronary angioplasty (PTCA) of the culprit artery restored a culprit artery CTFC (30.4 +/- 22.2) that was similar to that in the nonculprit artery at 90 min (30.2 +/- 13.5), but both were slower than normal CTFCs (21 +/- 3.1, p < 0.0005 for both). If flow in the nonculprit artery was abnormal (CTFC > or = 28 frames) then the CTFC after PTCA in the culprit artery was 17% slower (p = 0.01). Patients who died had slower global CTFCs (mean CTFC for the three arteries) than patients who survived (46.8 +/- 21.3, n = 47 vs. 39.4 +/- 16.7, n = 1,055, p = 0.02).
CONCLUSIONS: Acute MI slows flow globally, and slower global flow is associated with adverse outcomes. Relief of the culprit artery stenosis by PTCA restored culprit artery flow to that in the nonculprit artery, but both were 45% slower than normal flow.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520778     DOI: 10.1016/s0735-1097(99)00335-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  21 in total

1.  Near simultaneous atherothrombotic occlusion of two coronary arteries challenges the theory of the single vulnerable plaque.

Authors:  Thomas Bartel; Renate Hiemetzberger; Silvana Müller; Otmar Pachinger
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 2.  Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years.

Authors:  Vijayalakshmi Kunadian; Caitlin Harrigan; Cafer Zorkun; Alexandra M Palmer; Katherine J Ogando; Leah H Biller; Erin E Lord; Scott P Williams; Michelle E Lew; Lauren N Ciaglo; Jacqueline L Buros; Susan J Marble; William J Gibson; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2008-04-20       Impact factor: 2.300

3.  Importance of the TIMI frame count: implications for future trials.

Authors:  Mark A Appleby; Andrew D Michaels; Michael Chen; C Gibson Michael
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

Review 4.  Revascularization Strategies in STEMI with Multivessel Disease: Deciding on Culprit Versus Complete-Ad Hoc or Staged.

Authors:  Shalin Patel; Steven R Bailey
Journal:  Curr Cardiol Rep       Date:  2017-08-24       Impact factor: 2.931

Review 5.  Coronary intervention in patients with acute coronary syndrome: does every culprit lesion require revascularization?

Authors:  Sripal Bangalore; David P Faxon
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

6.  Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery.

Authors:  C Michael Gibson; Michael Chen; Brad G Angeja; Sabina A Murphy; Susan J Marble; Hal V Barron; Christopher P Cannon
Journal:  J Thromb Thrombolysis       Date:  2002-02       Impact factor: 2.300

7.  The assessment of non culprit coronary artery lesions in patients with ST segment elevated myocardial infarction and multivessel disease by control angiography with quantitative coronary angiography.

Authors:  Esra Dönmez; Mevlüt Koç; Taner Şeker; Yahya Kemal İçen; Murat Çayli
Journal:  Int J Cardiovasc Imaging       Date:  2016-07-22       Impact factor: 2.357

Review 8.  Coronary microvascular dysfunction in the clinical setting: from mystery to reality.

Authors:  Joerg Herrmann; Juan Carlos Kaski; Amir Lerman
Journal:  Eur Heart J       Date:  2012-08-22       Impact factor: 29.983

9.  The smoker's paradox: insights from the angiographic substudies of the TIMI trials.

Authors:  Brad G Angeja; Sarah Kermgard; Michael S Chen; Matthew McKay; Sabina A Murphy; Elliott M Antman; Christopher P Cannon; Eugene Braunwald; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

10.  Thrombin activatable fibrinolysis inhibitor : its role in slow coronary flow.

Authors:  M N Yildirim; Y Selcoki; S Uysal; A B Nacar; B Demircelik; H I Aydin; B Eryonucu
Journal:  Herz       Date:  2013-09-27       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.